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Abstract 
Purpose: Early reports suggested that transurethral resection (TURP) prior to permanent seed brachytherapy (BT) 
results in high incontinence rates. Guidelines consider prior TURP as a contra-indication to treatment, but improve-
ments in imaging and treatment planning may reduce this risk, and are investigated in this prospective study. 
Material and methods: 99 men with histologically proven low- to intermediate-risk, localized prostate cancer, with 
a history of TURP performed at least 3 months before BT procedure were enrolled. All patients received a permanent 
seed implant between March 2009 and June 2015. Intra-operative interactive planning was recommended to ensure 
optimal accuracy of seed placement during the procedure. No supplemental external beam was allowed. Target and 
organ at risk contouring, definition of clinical target volume (CTV), and dosimetric parameters followed the modified 
GEC-ESTRO guidelines for permanent seed implants, as described an earlier report of our group. Follow-up was 
scheduled every 3 months for the first year, and every 6 months afterwards, with minimum follow-up of 2 years. 
Study endpoints: the primary endpoint was the incidence of post-implant urinary incontinence. Secondary end-
points were the incidence of urinary and gastro-intestinal toxicity, the eventual impact on the sexual function, and the 
freedom from biochemical failure. 
Results: The median follow-up time for these 99 patients was 49 months (min. 24, max. 96). In this series, the incon-
tinence rate was 2% after TURP + BT and 2% in case of TURP + BT + re-TURP, ending up with a total urinary inconti-
nence rate of 4%. Acute and late urinary toxicities were extremely low. No significant late gastro-intestinal toxicity was 
seen, and the 5-year biochemical non-evidence of disease (bNED) was 93%. 
Conclusions: The excellent long-term results and low morbidity presented as well as many advantages of prostate 
brachytherapy over other treatments demonstrates that brachytherapy is an effective treatment for patients with trans-
urethral resection and organ-confined prostate cancer. 
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Purpose 
Transurethral resection of the prostate (TURP) is 
a surgical procedure performed under general or spinal 
anesthesia to remove the prostate tissue proximal to the 
verumontanum and distal to the bladder neck as treat-
ment for urinary obstruction. The surgeon removes as 
much tissue as necessary without penetrating the pros-
tatic capsule to allow the patient to void normally [1]. 
Low-dose-rate (LDR) 125I seed brachytherapy is an 
established treatment for men with localized low- and 
selected intermediate-risk prostate cancer. Both the 
American Brachytherapy Society (ABS) recommenda-
tions on permanent seed implant [2,3] and the Groupe 
de Curiethérapie-European Society for Radiotherapy 
and Oncology (GEC-ESTRO) guidelines [4] consider 
prior TURP as a relative contra-indication for prostate 
permanent seed brachytherapy. In many experienced 
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brachytherapy centers, a history of endoscopic resection 
of the prostate remains an absolute contra-indication 
to prostate brachytherapy, which is reflected in small 
number of publications in this area [5]. However, with 
more extensive experience, optimization of imaging 
techniques, and improved loading and dosimetry tech-
niques, the complication rate in this group of patients 
appears low. More recent reports [6,7,8,9] dealing with 
this issue suggest that brachytherapy can be safely per-
formed in a post-TURP patients’ group assuming mod-
ern imaging and optimized dosimetry techniques used. 
Unfortunately, the experience remains limited; reports 
are restricted and deal with small groups of patients. 
Against this background of early reports in the literature 
and further personal experience, the GEC-ESTRO Uro-
GEC group developed a protocol for consistent target 
and organ at risk contouring, definition of clinical tar-
get volume (CTV), and dosimetric parameters, based on 
the GEC-ESTRO guidelines for prostate seed implanta-
tion [10], but with some specific adaptation for the post-
TURP situation. Pilot data from the use of this protocol in 
a small cohort of patients has been presented [9] as well 
as a larger multi-center prospective planning study [11]. 
Due to wide range of different implantation techniques 
available in this multi-center environment, the variability 
between institutes has also been evaluated [11]. This fea-
sibility planning study confirmed that in a multi-center 
setting and experienced brachytherapy units can achieve 
the dose constraints defined in this modified protocol for 
patients undergoing prostate post-TURP brachythera-
py. With this reassurance, the Uro-GEC group of GEC- 
ESTRO proceeded with a prospective multi-center clinical 
study, in which patients were treated using this protocol 
with close evaluation of post-implant urinary function. 
Material and methods 
Selection of patients 
Men with histologically proven organ-confined, low- 
to intermediate-risk (D’Amico risk group definition) lo-
calized prostate cancer, defined as clinical stage T1c-T2b, 
N0, ISUP grade group 1, 2, or 3 (Gleason score 6 or 7), 
with prostate specific antigen (PSA) level < 20 ng/ml, 
and with a history of transurethral resection (TURP) 
performed at least 3 months before brachytherapy pro-
cedure were enrolled in this multi-center prospective 
clinical trial. Other inclusion criteria were a prostate 
volume measured on transrectal ultrasound of less than 
50 ml, the presence of a rim of prostate tissue of at least 
1 cm around the post-TURP urethral defect at the poste-
ro-lateral sides of the prostate, the absence of significant 
TURP-induced urinary incontinence, and an internation-
al prostate symptom score (IPSS) less than 15. The use 
of neo-adjuvant anti-androgen hormonal treatment was 
permitted to downsize the prostate volume or to cov-
er waiting time until the brachytherapy procedure. No 
adjuvant hormonal treatment was permitted. General 
inclusion criteria were a WHO performance status 0-1, 
the absence of contra-indication for anesthesia, no prior 
history of irradiation of the pelvis, the absence of oth-
er oncologic malignancy except adequately treated bas-
al cell carcinoma of the skin or other malignancy, from 
which the patient was disease-free for at least 5 years. All 
patients provided informed consent to participate. The 
log-rank test was used to compare biochemical non-evi-
dence of disease (bNED) between the subsets of patients 
analyzed. 
Treatment and follow-up 
All patients received transperineal ultrasound-guid-
ed LDR 125I seed brachytherapy monotherapy accord-
ing to the institute’s usual practice and technique. In-
tra-operative interactive planning was recommended to 
ensure optimal accuracy of seed placement during the 
procedure. No supplemental external beam was allowed. 
Target and organ at risk contouring, definition of CTV, 
and dosimetric parameters had to follow the modified 
GEC-ESTRO guidelines for permanent seed implants as 
described previously [11]. Follow-up was scheduled ev-
ery 3 months for the first year, then every 6 months, and 
included a physical examination, PSA, and prospective 
physician assessment of toxicity. 
Study endpoints and statistical evaluation 
The primary endpoint was the incidence of post-im-
plant urinary incontinence, which was defined as the 
need to use at least one pad per day. Secondary end-
points were the incidence of acute and late urinary tox-
icity, the incidence of gastro-intestinal side effects, and 
the impact on sexual function, all evaluated using the 
common terminology criteria for adverse effects (CT-
CAE) version 4.0, and the freedom from biochemical 
failure, defined as time from implant to date of PSA fail-
ure (Phoenix definition, nadir + 2 ng/ml). The probabil-
ities of freedom from biochemical failure and bPFS were 
estimated using the Kaplan-Meier method. To account 
for benign PSA bounce, patients were not considered to 
have PSA failures in case of a rise of the PSA by < 2 ng/ml 
during the first 24 months, followed by a subsequent 
non-hormonally induced PSA decrease. Late toxicity 
was defined as any toxicity occurring at > 12 months af-
ter implant. The 12-month cut-off was chosen on the ba-
sis of the half-life decay of 125I, 12 months being roughly 
6 half-lives. 
Results 
In all, 99 patients were entered in this prospective 
multi-center study. All patients received a permanent 
seed implant in one of the six participating centers be-
tween March 2009 and June 2015. The median follow-up 
was 49 (range, 24-96) months. Patient characteristics are 
presented in Table 1. 
Acute and chronic urinary toxicity 
Moderate increase in urinary irritation occurred in 
the first three months after the treatment. None of the 
patients developed a greater than grade I acute urinary 
toxicity. In addition, no acute urinary retention was seen. 
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19 out of the 99 patients (19%) developed a more than 
grade I late urinary toxicity during follow-up. Further 
evaluation of these 19 patients showed that in 2 patients, 
the complaints were related to a local recurrence, 2 pa-
tients presented with late onset urinary incontinence, and 
15 patients had major lower urinary tract symptoms. 
Four out of these 15 patients were successfully treated 
with symptomatic medication only; however, 11 patients 
underwent a re-TURP leading to a definitive re-TURP 
rate in this population of 10% (11 out of 99 patients). 
In 4 patients, this re-TURP was performed at 1-year, in 
2 patients at 18-months, in 3 patients at 2-year, and in 
2 patients at 4-year post-BT. Two out of these 11 patients 
who underwent a re-TURP developed urinary inconti-
nence, whereas 9 patients reported a clear relief of the 
lower urinary tract symptoms. At last follow-up, only 
8 out of the 99 patients (8%) still reported greater than 
grade I late urinary toxicity. Two of the 99 patients (2%) 
developed urinary incontinence after the brachytherapy 
procedure, and 2 patients (2%) developed urinary incon-
tinence after brachytherapy and re-TURP procedures. 
The total urinary incontinence rate at last follow-up is 
thus 4% (Figure 1). The percentage of re-TURP varied 
between different participating centers. Evaluating the 
4 major contributing centers, the incidence of re-TURP in 
center 1 was 10% (1 out of 10 patients), in center 2 it was 
3% (1 out of 29 patients), in center 3 it was 11% (3 out of 
27 patients), and in center 4 it was 28% (7 out of 25 pa-
tients). 
Lower gastrointestinal toxicity 
The observed lower gastrointestinal toxicity was ex-
tremely low. Some patients developed temporary grade I 
side effects. Only 1 out of the 99 patients (1%) developed 
a grade I late gastrointestinal toxicity during follow-up. 
Additionally, no patients presenting with perineal pain 
were reported. 
Oncological results 
For the entire cohort of 99 patients, 7 patients (7%) 
presented a biochemical recurrence. Two of these pa-
tients presented with a local recurrence, whereas 5 pa-
tients developed distance metastases. The overall and 
cancer-specific survival was 100% at 5 years. The 4- and 
5-year bNED were respectively 100% and 93% for the 
whole cohort (Figure 2). 
The actuarial bNED with ISUP grade groups was 
93.8% and 90.9% for patients with ISUP grade group 1 
and 2 (Gleason score of 6 and 7), respectively (p = 0.393). 
Tumor stage was not significantly associated (p = 0.974) 
Fig. 1. Urinary incontinence flow chart 
19 out of the 99 patients (19.2%) developed > grade I late urinary toxicity during follow-up
19 patients
Urinary > grade I late toxicity (8/99) at last follow-up = 8.08%,  
of which urinary incontinence (4/99) = 4.04% 
2 patients urinary incontinence
11 patients re-TURP
2 patients local recurrence 15 patients major LUTS
4 patients symptomatic therapy 
2 patients urinary incontinence 9 patients < G1 at the last follow-up
Table 1. Patient characteristics 
Characteristics Number of patients (%) 
T-classification  
T1a-b-c 51 (52%) 
T2a-b 49 (48%) 
ISUP grade group / Gleason score  
Grade group 1 / VI (3 + 3) 67 (67%)
Grade group 2 / VII (3 + 4) 26 (26%)
Grade group 3 / VII (4 + 3) 6 (6%)
Pretreatment PSA (ng/ml) Median 6.9 (min. 1.2, max. 16) 
Risk level  
Low-risk 54 (55%) 
Intermediate-risk 45 (45%) 
Androgen deprivation therapy 0 (0%) 
Median follow-up time 49 months (min. 24, max. 96) 
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with biochemical control, neither was initial PSA or risk 
group (p = 0.56). 
Discussion 
The incidence of urinary incontinence in patients 
treated with brachytherapy following TURP is low at 
4%. Overall, there was a low incidence of acute and late 
urinary and gastro-intestinal toxicity combined with ex-
cellent oncological results. These results are in concor-
dance with the experience of other institutions [12,13,14, 
15,16,17] and results seen in a non-TURP population 
[18,19,20,21,22,23]. 
In our series, the incontinence rate was 2% after TURP 
+ BT and 2% in case of TURP + BT + re-TURP, with a total 
urinary incontinence rate of 4%. 
Both the ABS recommendations on permanent seed 
implant [2,3] and the GEC-ESTRO guidelines [4] consid-
er prior transurethral resection of the prostate (TURP), 
a relative contra-indication for prostate permanent seed 
brachytherapy. These recommendations were principally 
based on an early report from the Seattle group [5], de-
scribing their initial experience, and reporting a major 
risk of significant toxicity and urinary incontinence in 
brachytherapy patients who had undergone prior TURP. 
This study indicated a 17% risk of urinary incontinence. 
However, subsequently, Wallner et al. reported only 
a 6% incontinence rate at 3 years in 19 patients treated 
with prostate seed implant after previous TURP, and 
there have been a number of retrospective reports of 
post-TURP brachytherapy with low urinary toxicity rates 
[6,8,9,24,25,26]. These are shown in Table 2. 
A further feature of this series is the number of patients 
undergoing a repeat TURP procedure after brachythera-
py. The precise indications for this have not been collect-
ed. They may represent patients with urethral stricture 
or benign regrowth, but it is reassuring to note that the 
likelihood of incontinence in this group is no higher than 
the patients who did not need further intervention. 
The strength of these results is that they are likely to 
reflect real world practice across different centers in dif-
ferent countries. The detailed dosimetric guidelines are 
an important component of this and should be closely 
followed in post-TURP patients. These patients have al-
ternative options for treatment including prostatectomy 
or external beam radiotherapy; this data suggests that the 
risk of incontinence with LDR brachytherapy after TURP 
is no greater than either of these alternatives. Unfortu-
nately, data on sexual function was incomplete and is not 
sufficient to provide a useful estimate. Similarly, we can-
not comment on the need for ongoing medication such as 
alpha blocking drugs to maintain urinary function after 
brachytherapy. 
Our study is the first multi-center prospective study 
evaluating the acute and late urinary and gastro-intesti-
nal tolerance, the incontinence rate as well as the onco-
logical outcomes in patients treated by TURP, followed 
by a prostate seed implant. It has been shown that 
brachytherapy for patients with a prior TURP is not only 
effective, but also with low induced toxicity with careful 
patient selection, at least 3 months from TURP and seed 
implant, using dosimetry adapted for the post-TURP 
anatomy. 
Conclusions 
With the present prospective data, added to the ex-
isting retrospective literature, and with more experience 
in the field as well as the optimization of the imaging 
techniques and improved loading and dosimetry tech-
niques following the adapted guidelines concerning the 
specific post-TURP situation, prostate seed implants can 
be performed with excellent oncological results and low 
urinary and gastro-intestinal toxicity. 
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Table 2. Literature list
Publication Number of patients Urinary incontinence rate 
Wallner et al. (1997) [6] 19 6% (at 3 years) 
Moran et al. (2004) [8] 171 N.A. 
Claros et al. (2009) [24] 16 0% (average follow-up 30 months) 
Salembier et al. (2009) [9] 51 0% (mean follow-up 18 months) 
Anguelo Latorre et al. (2013) [25] 56 1% (mean follow-up 100 months) 
Prada et al. (2016) [26] 57 1.7% (mean follow-up 104 months) 
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